Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial

MLA

Vera Gorbunova, et al. “Trifluridine/Tipiracil versus Placebo in Patients with Heavily Pretreated Metastatic Gastric Cancer (TAGS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet Oncology, vol. 19, Nov. 2018, pp. 1437–48. EBSCOhost, https://doi.org/10.1016/s1470-2045(18)30739-3.

APA

Vera Gorbunova, Giordano D. Beretta, Kazuhiro Nishikawa, Hendrik-Tobias Arkenau, Maria Alsina, Kohei Shitara, M Dvorkin, Aliaksandr Prokharau, Suayib Yalcin, Kazumasa Fujitani, Josep Tabernero, Robert Winkler, Lukas Makris, Eric Van Cutsem, Wasat Mansoor, Michele Ghidini, C. Faustino, Edvard Zhavrid, Ayumu Hosokawa, … Toshihiko Doi. (2018). Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 19, 1437–1448. https://doi.org/10.1016/s1470-2045(18)30739-3

Chicago

Vera Gorbunova, Giordano D. Beretta, Kazuhiro Nishikawa, Hendrik-Tobias Arkenau, Maria Alsina, Kohei Shitara, M Dvorkin, et al. 2018. “Trifluridine/Tipiracil versus Placebo in Patients with Heavily Pretreated Metastatic Gastric Cancer (TAGS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.” The Lancet Oncology 19 (November): 1437–48. doi:10.1016/s1470-2045(18)30739-3.